Ligand id: 8959

Name: ensartinib

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 113.68
Molecular weight 546.13
XLogP 3.66
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
There are a number of ongoing clinical trials that are evaluating X-396 (ensartinib) in a variety of solid tumour types. The most advanced is a Phase 3 trial that is comparing ensartinib to crizotinib in ALK-rearranged NSCLC (NCT02767804). A Phase 2 study is underway to determine the efficacy of genetic screening as a route to personalising treatment for childhood non-Hodgkin lymphoma, in which ensartinib is one of the drugs available to test. Click here to link to ClinicalTrials.gov's full list of current ensartinib trials.